Bjørn Kantsø

Dr. Kantsø has +15 years of experience within the field of bacterial vaccines. Dr. Kantsø received a M.Sc in Biotechnology from the Technical University of Denmark and a Ph.D from the University of Copenhagen. Dr. Kantsø joined MinervaX in 2021, and currently serves as Chief Technology Officer and Head of Chemistry Manufacturing and Controls (CMC). Prior to MinervaX, Dr. Kantsø was at Lundbeck, where he helped build the Biopharmaceutical Division. Prior to Lundbeck, Dr. Kantsø was head of a QC department at the CMO AGC Biologics (former CMC Biologics). Prior to AG Biologics Dr. Kantsø served as laboratory leader and assay development scientist at Statens Serum Institut.